Clinical Trial Update: FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years [Phase 2]

View source ↗

Summary

Phase 2 follow-up study of FSME IMMUN NEW in children aged 1 to 6 years for tick-borne encephalitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME IMMUN NEW (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Phase 2 | Status: COMPLETED